Waltham, Massachusetts, July 28, 2026
Dyne Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for DYNE-302, enabling the company to initiate a Phase 1 clinical trial in patients with facioscapulohumeral muscular dystrophy (FSHD). The milestone marks Dyne’s third clinical development program leveraging its proprietary FORCE™ platform, which is designed to improve targeted delivery of therapeutics to muscle tissue and ultimately deliver meaningful functional improvement in rare neuromuscular diseases. FSHD is one of the most common inherited muscular dystrophies and currently has no approved therapies, making the advancement of DYNE-302 an important development for patients living with this progressive genetic disorder. The investigational therapy combines a transferrin receptor 1 (TfR1)-targeting antigen-binding fragment (Fab) with a small interfering RNA (siRNA) specifically designed to suppress DUX4 mRNA, the underlying genetic driver responsible for disease progression. By directly targeting the root cause of FSHD, Dyne aims to develop a disease-modifying treatment capable of improving muscle function while addressing a significant unmet medical need.
FDA Clearance Advances Third FORCE™ Clinical Program
The FDA’s IND clearance allows Dyne Therapeutics to begin a randomized, placebo-controlled, double-blind, multiple ascending dose Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of DYNE-302 in ambulatory adults with FSHD. The initial study cohort will enroll nine participants, randomized in a 2:1 ratio to receive either DYNE-302 or placebo through intravenous administration every four weeks. Following completion of the first cohort, the company intends to investigate higher dose levels and less frequent dosing schedules to optimize treatment delivery. Participants who successfully complete the placebo-controlled portion of the study may continue into a 96-week open-label extension, allowing researchers to evaluate the long-term safety and durability of treatment. Dyne also confirmed its intention to pursue the traditional U.S. regulatory approval pathway should clinical development continue successfully.
Targeting DUX4 to Address the Root Cause of FSHD
Unlike therapies designed primarily to manage symptoms, DYNE-302 is engineered to suppress DUX4 expression, the key genetic abnormality responsible for skeletal muscle degeneration in facioscapulohumeral muscular dystrophy. The investigational therapy utilizes Dyne’s FORCE™ platform, enabling targeted muscle delivery through TfR1-mediated transport, while its highly specific siRNA payload reduces production of the harmful DUX4 transcriptome. According to preclinical findings, administration of DYNE-302 produced robust knockdown of DUX4-related gene expression, significantly reduced muscle fiber damage, and generated measurable functional improvement in severe disease models. These encouraging results suggest that existing skeletal muscle injury associated with FSHD may have the potential to be reversed through effective suppression of DUX4 activity. The Phase 1 study will further evaluate biological activity using changes in the DUX4 transcriptome and plasma KHDC1L, a biomarker independently identified by Dyne as being regulated by DUX4 in FSHD.
Advertisement
Strengthening Dyne’s Rare Neuromuscular Disease Pipeline
The advancement of DYNE-302 further expands Dyne Therapeutics’ growing pipeline of precision therapies targeting rare neuromuscular diseases. The company’s FORCE™ platform is already supporting clinical programs in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), while additional research programs continue in Pompe disease and other DMD mutations. With no currently approved therapies available for FSHD, the FDA clearance represents an important step toward developing a treatment capable of modifying disease progression rather than simply alleviating symptoms. By combining targeted muscle delivery, RNA interference technology, and precision genetic medicine, Dyne continues to strengthen its position in the rapidly evolving field of rare disease therapeutics, offering new hope for individuals living with debilitating inherited muscle disorders while advancing innovative approaches to neuromuscular drug development.
Source: Dyne Therapeutics press release
